Jee In Kang1, Hae-Jeong Park, Se Joo Kim, Kyung Ran Kim, Su Young Lee, Eun Lee, Suk Kyoon An, Jun Soo Kwon, Jong Doo Lee. 1. *To whom correspondence should be addressed; Department of Psychiatry, Severance Mental Health Hospital, Yonsei University Health System, 119, 1926 Beon-gil, Gyeongchung-daero, Gwangju-si, Gyeonggi-do 464-100, South Korea; tel: +82-31-760-9404, fax: +82-31-761-7582, e-mail: ansk@yuhs.ac.
Abstract
BACKGROUND: Altered transmission of gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter, may contribute to the development of schizophrenia. The purpose of the present study was to investigate the presence of GABA-A/benzodiazepine (BZ) receptor binding abnormalities in individuals at ultra-high risk (UHR) for psychosis in comparison with normal controls using [(18)F]-fluoroflumazenil (FFMZ) positron emission tomography (PET). In particular, we set regions of interest in the striatum (caudate, putamen, and nucleus accumbens) and medial temporal area (hippocampus and parahippocampal gyrus). METHODS: Eleven BZ-naive people at UHR and 15 normal controls underwent PET scanning using [(18)F]-FFMZ to measure GABA-A/BZ receptor binding potential. The regional group differences between UHR individuals and normal controls were analyzed using Statistical Parametric Mapping 8 software. Participants were evaluated using the structured interview for prodromal syndromes and neurocognitive function tasks. RESULTS: People at UHR demonstrated significantly reduced binding potential of GABA-A/BZ receptors in the right caudate. CONCLUSIONS: Altered GABAergic transmission and/or the imbalance of inhibitory and excitatory systems in the striatum may be present at the putative prodromal stage and play a pivotal role in the pathophysiology of psychosis.
BACKGROUND: Altered transmission of gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter, may contribute to the development of schizophrenia. The purpose of the present study was to investigate the presence of GABA-A/benzodiazepine (BZ) receptor binding abnormalities in individuals at ultra-high risk (UHR) for psychosis in comparison with normal controls using [(18)F]-fluoroflumazenil (FFMZ) positron emission tomography (PET). In particular, we set regions of interest in the striatum (caudate, putamen, and nucleus accumbens) and medial temporal area (hippocampus and parahippocampal gyrus). METHODS: Eleven BZ-naive people at UHR and 15 normal controls underwent PET scanning using [(18)F]-FFMZ to measure GABA-A/BZ receptor binding potential. The regional group differences between UHR individuals and normal controls were analyzed using Statistical Parametric Mapping 8 software. Participants were evaluated using the structured interview for prodromal syndromes and neurocognitive function tasks. RESULTS:People at UHR demonstrated significantly reduced binding potential of GABA-A/BZ receptors in the right caudate. CONCLUSIONS: Altered GABAergic transmission and/or the imbalance of inhibitory and excitatory systems in the striatum may be present at the putative prodromal stage and play a pivotal role in the pathophysiology of psychosis.
Entities:
Keywords:
GABA; PET; caudate; fluoroflumazenil; risk for psychosis; schizophrenia; ultra-high
Authors: Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson Journal: J Cereb Blood Flow Metab Date: 2007-05-09 Impact factor: 6.200
Authors: W Gordon Frankle; Raymond Y Cho; Rajesh Narendran; N Scott Mason; Shivangi Vora; Maralee Litschge; Julie C Price; David A Lewis; Chester A Mathis Journal: Neuropsychopharmacology Date: 2008-07-09 Impact factor: 7.853
Authors: Elina Salmi; Sargo Aalto; Jussi Hirvonen; Jaakko W Långsjö; Anu T Maksimow; Vesa Oikonen; Liisa Metsähonkala; Jussi Virkkala; Kjell Någren; Harry Scheinin Journal: Neuroimage Date: 2008-03-04 Impact factor: 6.556
Authors: Markus Mitterhauser; Wolfgang Wadsak; Leila Wabnegger; Leonhard-Key Mien; Stefan Tögel; Oliver Langer; Werner Sieghart; Helmut Viernstein; Kurt Kletter; Robert Dudczak Journal: Nucl Med Biol Date: 2004-02 Impact factor: 2.408
Authors: Clement C Zai; Arun K Tiwari; Nicole King; Vincenzo De Luca; Daniel J Mueller; Sajid Shaikh; Greg W H Wong; Herbert Y Meltzer; Jeffrey A Lieberman; James L Kennedy Journal: Schizophr Res Date: 2009-08-13 Impact factor: 4.939
Authors: Minji Bang; Jee In Kang; Se Joo Kim; Jin Young Park; Kyung Ran Kim; Su Young Lee; Kyungmee Park; Eun Lee; Seung-Koo Lee; Suk Kyoon An Journal: Schizophr Bull Date: 2019-10-24 Impact factor: 9.306
Authors: Heidi W Thermenos; Richard J Juelich; Samantha R DiChiara; Raquelle I Mesholam-Gately; Kristen A Woodberry; Joanne Wojcik; Nikos Makris; Matcheri S Keshavan; Susan Whitfield-Gabrieli; Tsung-Ung W Woo; Tracey L Petryshen; Jill M Goldstein; Martha E Shenton; Robert W McCarley; Larry J Seidman Journal: Schizophr Res Date: 2016-03-07 Impact factor: 4.939
Authors: Teresa Vargas; Hannah Snyder; Marie Banich; Rae Newberry; Stewart A Shankman; Gregory P Strauss; Vijay Anand Mittal Journal: Schizophr Res Date: 2018-06-20 Impact factor: 4.939
Authors: T Winton-Brown; A Schmidt; J P Roiser; O D Howes; A Egerton; P Fusar-Poli; N Bunzeck; A A Grace; E Duzel; S Kapur; P McGuire Journal: Transl Psychiatry Date: 2017-10-03 Impact factor: 6.222